ArticleFrontiers in immunology2026
Janus kinase inhibitor use and incident dry eye disease in rheumatoid arthritis: a real-world cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To examine the association between systemic Janus kinase (JAK) inhibitor use and the incidence of newly diagnosed dry eye disease (DED) in patients with rheumatoid arthritis (RA). Methods: This multi-institutional retrospective cohort study used de-identified electronic health records from the United States Collaborative Network. Adults aged 18 years or older with RA were categorized according to systemic JAK inhibitor use or non-use. A secondary active-comparator analysis compared JAK inhibitor users with rituximab-treated patients. Propensity score matching was performed to balance demographic characteristics, comorbidities, medication history, ocular conditions, and healthcare utilization. The primary outcome was newly diagnosed DED. Time-to-event analyses were conducted using Kaplan-Meier methods and Cox proportional hazards models. Results: A total of 25,149 JAK inhibitor users and 150,250 non-users with RA were identified. After matching, each cohort contained 23,343 patients with balanced baseline characteristics. JAK inhibitor use was associated with a lower incidence of newly diagnosed DED compared with non-use within 1 year of follow-up (hazard ratio [HR], 0.633; 95% CI, 0.545-0.736). In the secondary active-comparator analysis, 6,637 JAK inhibitor users were matched to 6,637 rituximab-treated patients, and JAK inhibitor use remained associated with a lower incidence of newly diagnosed DED (HR, 0.613; 95% CI, 0.476-0.791). Individual-agent analyses showed directionally consistent associations for tofacitinib and upadacitinib. Findings were consistent across sensitivity analyses using varying follow-up durations and landmark definitions. Conclusion: In this large real-world cohort study, JAK inhibitor use was associated with a lower incidence of newly diagnosed DED among patients with RA, with similar findings in a rituximab active-comparator analysis. However, the observational design, residual confounding, and coding-based outcome definition preclude causal inference. Prospective studies incorporating standardized ocular surface assessments and direct RA disease activity measures are needed to clarify the clinical relationship between systemic JAK inhibition and DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.